Oyster Point Pharma (OYST) 10-Q2021 Q2 Quarterly report

Filed: 5 Aug 21, 4:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAV, absence, affiliated, affirmative, agent, alpha, annum, appeal, APT, argued, automatic, Bank, bankruptcy, bear, beta, bioRxiv, bona, buyout, campaign, casualty, cell, cellular, challenge, chosen, committee, convenience, Cosmetic, covenant, customary, daily, default, dictate, dismissed, dividend, effort, eighty, Enriched, entity, entry, equal, equivalent, ERISA, ETF, fide, floor, fundamental, gene, gland, grace, headquartered, Highlighting, history, Hong, hundred, inaccuracy, inclusive, inhibit, injection, insolvency, instructed, intralacrimal, intranasal, inventory, iv, ix, Ji, joint, Keratopathy, Kong, Lastly, lawsuit, lender, length, leverage, loan, LP, Macau, macroscopic, mainland, mandatorily, margin, Maryland, maturity, MFN, microscopic, model, modulate, motion, Nasdaq, Nerve, NGF, nose, ophthalmic, OrbiMed, outbound, overnight, phage, pledge, Potent, prepay, prepayment, preprint, procedural, prophylactic, quartile, rabbit, region, repayment, retirement, RNA, RTW, server, Shanghai, simpinicline, sixty, stemming, subgenomic, substance, sum, Taiwan, Territory, tranche, transduction, uncured, underway, undischarged, variant, vector, vi, vii, viii, viral, written, xi, Xing, yield, York

Removed: advancement, back, Circuit, decision, deploy, extend, gain, invalid, Judge, ocular, professional, reclassified, remanded, ruled, surface, targeting, upheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated OYST transcripts

OYST similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Oyster Point Pharma, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Nau, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:


(1)			The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)			The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 5, 2021	By:	/s/ Jeffrey Nau
		Jeffrey Nau, Ph.D., M.M.S.
		President and Chief Executive Officer
		(Principal Executive Officer)